Janux Therapeutics | Novel T Cell Immunotherapies Janux is developing novel immunotherapies that selectively modulate T cells to fight cancer and autoimmune diseases without causing systemic safety issues
Analyst deems Januxs stock spiral an overreaction Almost exactly one year ago, Janux Therapeutics unveiled early data for its investigational T-cell engager that wowed investors and analysts alike But the biotech’s newest update has failed to
Janux Announces Encouraging Efficacy and Safety Profile from Ongoing . . . Janux’s second clinical candidate, JANX008, is a TRACTr that targets epidermal growth factor receptor (EGFR) and is being studied in a Phase 1 clinical trial for the treatment of multiple solid cancers including colorectal carcinoma, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell
Janux - Investor Relations - Investors Media Janux is a clinical-stage company developing precision-engineered immunotherapies that have the potential to generate potent and durable immune responses without causing systemic safety issues